Sign In
Buy BMRN
$60.02
-0.560 (-0.92%)
At Close: Jul 31, 2026
BioMarin Pharmaceutical Inc. $BMRN Shares Sold by Envestnet Asset Management Inc.
05:05am, Monday, 02'nd Mar 2026
Envestnet Asset Management Inc. trimmed its position in BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 50.4% in the undefined quarter, according to the company in its most recent disclosure with the S
Treatment with PALYNZIQ led to statistically significant blood phenylalanine (Phe) lowering compared to diet alone in pivotal Phase 3 PEGASUS study PALYNZIQ is the only enzyme substitution therapy app
DNB Asset Management AS Acquires 154,954 Shares of BioMarin Pharmaceutical Inc. $BMRN
04:27am, Friday, 27'th Feb 2026
DNB Asset Management AS increased its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 13.8% in the undefined quarter, according to its most recent filing with the SEC. The fund ow
BMRN Beats on Q4 Earnings, to Withdraw Roctavian From Market
12:36pm, Tuesday, 24'th Feb 2026
BioMarin beats Q4 earnings estimates as Voxzogo drives year-over-year revenue growth. The company decides to voluntarily withdraw its hemophilia gene therapy.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock
10:50am, Tuesday, 24'th Feb 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BioMarin to Participate in Four Upcoming Investor Conferences in March
09:00am, Tuesday, 24'th Feb 2026
TD Cowen 46th Annual Health Care Conference on Wednesday, March 4, 2026 Leerink 2026 Global Healthcare Conference on Monday, March 9, 2026 Jefferies 2026 Biotech on the Beach Summit on Tuesday, March
BioMarin Pharmaceutical Inc. (BMRN) Q4 2025 Earnings Call Transcript
11:14pm, Monday, 23'rd Feb 2026
BioMarin Pharmaceutical Inc. (BMRN) Q4 2025 Earnings Call Transcript
Compared to Estimates, BioMarin (BMRN) Q4 Earnings: A Look at Key Metrics
09:01pm, Monday, 23'rd Feb 2026
Although the revenue and EPS for BioMarin (BMRN) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Str
BioMarin Pharmaceutical (BMRN) Beats Q4 Earnings and Revenue Estimates
08:26pm, Monday, 23'rd Feb 2026
BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.92 per share a year ago.
BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results
04:05pm, Monday, 23'rd Feb 2026
Full-year 2025 Total Revenues Increased 13% Y/Y to $3.2 Billion, Led by 9% Revenue Growth for Enzyme Therapies and 26% Revenue Growth for VOXZOGO® Fourth Quarter 2025 Total Revenues Increased 17% Y/Y
Countdown to BioMarin (BMRN) Q4 Earnings: Wall Street Forecasts for Key Metrics
10:16am, Thursday, 19'th Feb 2026
Besides Wall Street's top-and-bottom-line estimates for BioMarin (BMRN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the qu
SAN RAFAEL, Calif., Feb. 17, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a confe
What to Expect From These Drug/Biotech Players This Earnings Season?
03:16pm, Monday, 16'th Feb 2026
Let's take a closer look at what awaits Bausch Health, Amicus Therapeutics, BioMarin Pharmaceutical, Insmed and Madrigal Pharmaceuticals as they prepare to report quarterly results this week.
BioMarin Announces Closing of Private Offering of Senior Notes
04:05pm, Thursday, 12'th Feb 2026
SAN RAFAEL, Calif., Feb. 12, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it closed its previously announced offering of $850 million of 5.500% se
Earnings Preview: BioMarin Pharmaceutical (BMRN) Q4 Earnings Expected to Decline
11:02am, Wednesday, 11'th Feb 2026
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
